Profusa seeks shareholder approval for second reverse split, massive dilutive acquisition, management shares, and convertible debt conversion to avoid delisting.

summarizeSummary

Profusa is holding an annual meeting to vote on a second reverse stock split, a highly dilutive acquisition, significant management share grants, convertible note conversions, and an expanded equity plan, all aimed at addressing financial distress and Nasdaq delisting threats.

check_boxKey Events

• Proposed Second Reverse Stock Split

  Shareholders will vote on a reverse stock split ranging from 1-for-10 to 1-for-200, intended to regain Nasdaq's minimum bid price compliance. This follows a 1-for-75 reverse split on February 9, 2026, which did not resolve the delisting issue.

• Highly Dilutive Acquisition Financing

  Approval is sought for the issuance of a newly created series of convertible preferred stock to Bio Insights LLC as consideration for the $30 million acquisition of PanOmics Assay know-how. This represents an extremely large transaction relative to Profusa's market capitalization.

• Significant Management Share Grant

  A proposal to issue shares equal to 12% of the fully diluted common stock outstanding to the CEO and CFO for retention purposes, which will result in substantial dilution for existing shareholders.

• Convertible Note Conversion Approval

  Shareholders will vote on approving the potential issuance of shares in excess of 19.99% of outstanding common stock upon the conversion of a $1.87 million promissory note held by NorthView Sponsor I LLC, with a floor conversion price of $0.35 per share.

auto_awesomeAnalysis

Profusa, a company with a market capitalization of less than $2 million, is seeking shareholder approval for a series of highly dilutive measures critical for its continued operations and Nasdaq listing. These proposals include a second reverse stock split (1-for-10 to 1-for-200) to address ongoing delisting threats, following a previous 1-for-75 reverse split that failed to achieve sustained compliance. Additionally, shareholders are asked to approve the issuance of $30 million in convertible preferred stock for an acquisition, which represents an extraordinary amount relative to the company's current valuation. Further dilution is proposed through a grant of 12% of fully diluted shares to management for retention, the conversion of a $1.87 million convertible note into up to 5.34 million shares, and a significant increase in the equity incentive plan share pool. These combined actions indicate severe financial distress and a desperate attempt to secure capital and maintain listing, with substantial dilution for existing shareholders.